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Background: Despite the availability of five guidelines for the diagnosis of fetal alcohol spectrum disorders (FASD),
there is no national endorsement for their use in diagnosis in Australia. In this study we aimed to describe health
professionals’ perceptions about the adoption of existing guidelines for the diagnosis of FASD in Australia and
identify implications for the development of national guidelines.
Methods: We surveyed 130 Australian and 9 international health professionals with expertise or involvement in the
screening or diagnosis of FASD. An online questionnaire was used to evaluate participants’ familiarity with and use
of five existing diagnostic guidelines for FASD, and to assess their perceptions about the adoption of these
guidelines in Australia.
Results: Of the 139 participants surveyed, 84 Australian and 8 international health professionals (66.2%) responded
to the questions on existing diagnostic guidelines. Participants most frequently reported using the University of
Washington 4-Digit Diagnostic Code (27.2%) and the Canadian guidelines (18.5%) for diagnosis. These two
guidelines were also most frequently recommended for adoption in Australia: 32.5% of the 40 participants who
were familiar with the University of Washington 4-Digit Diagnostic Code recommended adoption of this guideline
in Australia, and 30.8% of the 26 participants who were familiar with the Canadian guidelines recommended
adoption of this guideline in Australia. However, for the majority of guidelines examined, most participants were
unsure whether they should be adopted in Australia. The adoption of existing guidelines in Australia was perceived
to be limited by: their lack of evidence base, including the appropriateness of established reference standards for
the Australian population; their complexity; the need for training and support to use the guidelines; and the lack of
an interdisciplinary and interagency model to support service delivery in Australia.
Conclusions: Participants indicated some support for the adoption of the University of Washington or Canadian
guidelines for FASD diagnosis; however, concerns were raised about the adoption of these diagnostic guidelines in
their current form. Australian diagnostic guidelines will require evaluation to establish their validity in the Australian
context, and a comprehensive implementation model is needed to facilitate improved diagnostic capacity in
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Criteria for the diagnosis of fetal alcohol spectrum disor-
ders (FASD) have been available since 1973 and refined
periodically [1]. In 1996, the United States Congress
charged the Institute of Medicine (IOM) with evaluating
existing diagnostic criteria and formulating the best pos-
sible diagnostic guidelines reflective of current know-
ledge [2]. While the IOM guidelines reflected an
important advancement in FASD diagnosis, the guide-
lines remained intentionally broad and conceptual rather
than specific and operational [1]. Progress in the field
since the publication of the IOM diagnostic criteria has
provided the basis for four additional guidelines: the
University of Washington (UW) FASD 4-Digit Code in
1997 [3], updated in 2004 [4]; the Centers for Disease
Control and Prevention (CDC) FAS guidelines in 2004
[5]; the Hoyme clarification of the IOM diagnostic cri-
teria (Hoyme) in January 2005 [6], and the Canadian
FASD guidelines (Canadian) in March 2005 [7]. While
areas of debate still exist, these four subsequent guide-
lines have reached consensus on two fundamental issues:
i) that FASD diagnostic evaluation is best conducted by
an interdisciplinary team of professionals, and ii) that
diagnosis should be based on rigorously case-defined
and validated FASD diagnostic guidelines [1]. Despite
the availability of FASD diagnostic guidelines for over a
decade, many countries, including Australia, have no na-
tionally endorsed guidelines for the diagnosis of FASD.
Reported inconsistencies in the methods used to diag-
nose FAS in Australia [8,9] and FASD in England [10]
suggest that there is limited awareness of appropriate
diagnostic guidelines among some clinicians who diag-
nose FASD. The accurate and reliable diagnosis of FASD
presents numerous challenges [11], and opinion is
divided on the most appropriate diagnostic methods [1].
In an international survey of diagnostic services for
FASD conducted during 2006, only 67.6% of clinics fol-
lowed a single published diagnostic guideline [12], indi-
cating little agreement on the most appropriate
diagnostic criteria. Among the clinics that followed a
single published diagnostic guideline, 61% used the UW
FASD 4-Digit Diagnostic Code [4] and 35% used Hoyme
and colleagues’ [6] revision of the IOM guidelines [2].
Among the clinics that used a combination of guidelines
or their own adaption of published criteria for diagnosis,
73% used a combination that included the UW or the
IOM guidelines, highlighting their frequent use or adap-
tion in the clinical context.
Until recently there has been no dedicated specialised
capacity for FASD diagnosis in Australia, little coordin-
ation of service provision, and limited resources to pro-
vide the services required by affected individuals and
their families. FASD is likely under-diagnosed in Austra-
lia, and there is an urgent need to increase diagnosticand management capacity [8,9,13,14]. The adoption of
the UW guidelines in Australia has been proposed as an
evidence based, sensitive and specific method for the
diagnosis of FASD that can account for exposures to
other teratogens during pregnancy as well as early life
events [9]. Although it is difficult to accurately estimate
the prevalence of FASD [10,15], the use of standardised,
evidence based diagnostic methods can facilitate mean-
ingful comparison of clinical data [12], provide valuable
information about prevalence, and assist planning for
the delivery of services for affected individuals [9].
Health professionals’ perceptions about the validity of
diagnostic guidelines for FASD, including whether the
guidelines produce results that are consistent with their
clinical impression, are considered of central importance
in determining which diagnostic guidelines for FASD are
ultimately used in practice [16]. We require an improved
understanding of health professionals’ use of existing
guidelines for the diagnosis of FASD in Australia, of fac-
tors that influence the use of specific guidelines, and of
the suitability of existing guidelines for use in Australia.
In this study we aimed to describe health professionals’
perceptions about the adoption of existing guidelines for
the diagnosis of FASD in Australia and identify implica-
tions for the development of national guidelines.Methods
We used an online cross-sectional survey to assess
health professionals’ familiarity with and use of existing
diagnostic guidelines for FASD, and their perceptions
about the adoption of existing diagnostic guidelines in
Australia.Participant recruitment
We sought to survey a range of health professionals who
had expertise in or experience with the screening or
diagnosis of FASD, and who were likely to have some
knowledge of existing diagnostic methods and guide-
lines. As health professionals in Australia generally have
poor awareness of the diagnostic criteria for FASD
[17,18], participants were recruited using three purpos-
ive sampling strategies [19] as summarised in Table 1. A
formal invitation was sent via email to: 57 medical prac-
titioners who had reported a diagnosis of FAS to the
Australian Paediatric Surveillance Unit (APSU) surveil-
lance study conducted in 2001–2004 [8]; 128 health pro-
fessionals who were identified by the study investigators
as having experience or expertise in FASD screening or
diagnosis, including 14 international experts; and 35
individuals who responded to the canvassing of health
professional organisations (including national, state and
territory medical and nursing groups) calling for indivi-
duals who had relevant experience or expertise.
Table 1 Participant recruitment and response to survey questions about existing diagnostic guidelines
Recruitment category Invited Surveyed Responded
n n % invited n % invited % surveyed
APSU† 57 40 70.2 20 35.1 50.0
Australian health professionals 114 59 51.8 44 38.6 74.6
Australian professional organizations{ 35 31 88.6 20 57.1 64.5
International health professionals 14 9 64.3 8 57.1 88.9
Total 220 139 63.2 92 41.8 66.2
†APSU-Australian Paediatric Surveillance Unit.
{ Australian health professional organisations included national, state and territory medical and nursing groups.
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recruited through the APSU, all were included in the
study apart from 17 who either actively declined to par-
ticipate or who could not be contacted (based on an in-
valid email address or an automated email reply). Invited
health professionals were only surveyed if they actively
indicated their willingness to participate in the study.
Among the 163 invited health professionals, 64 either
did not respond to the email invitation to participate, or
declined to participate. The questionnaire was distribu-
ted to 139 individuals, including 40 who had reported a
diagnosis of FAS to the APSU, 68 who were identified as
having experience or expertise in FASD screening or
diagnosis (including 9 international experts) and 31 who
were recruited from professional organisations.Questionnaire
Five existing diagnostic guidelines were identified in a
systematic review of the prevention, diagnosis and man-
agement of FASD [20]: the IOM diagnostic criteria [2],
the UW FASD 4-Digit Diagnostic Code [4], the Hoyme
clarification of the Institute of Medicine diagnostic cri-
teria [6], the CDC guidelines for referral and diagnosis
of FAS [21], and the Canadian guidelines for diagnosis
[7].
Participants were initially asked if they were familiar
with each of the five diagnostic guidelines and provided
with the response options of ‘yes’ or ‘no’. If participants
were familiar with a guideline, three additional questions
were asked for each guideline: ‘Have you used this sys-
tem or guideline?’, ‘Should this system or guideline be
adopted as the standard for diagnosis in Australia?’ and
‘Are you aware of, or have you encountered, any limita-
tions of this system or guideline?’ The response options
of ‘yes’, ‘unsure’ and ‘no’ were provided for these three
questions, and a fourth option of ‘no comment’ was also
included for the questions on guideline adoption and
limitations to allow participants to indicate that these
questions were outside their area of expertise.
If any limitations of a guideline were identified, partici-
pants were asked to describe the limitations. Twoadditional open ended questions sought qualitative infor-
mation on factors influencing the use of guidelines and
perceptions about the adoption of existing guidelines for
use in Australia. All participants were asked to ‘Please
describe why you use, or don’t use, the diagnostic sys-
tems or guidelines listed above’ and to ‘Enter any com-
ments about the adoption of existing FASD diagnostic
systems or guidelines for use in Australia’. Demographic
characteristics including occupation, country of resi-
dence, sex, experience in FASD diagnosis, and comple-
tion of training in FASD diagnosis were also assessed.Questionnaire administration
The questionnaire on perceptions of existing diagnostic
systems was administered as a component of a large sur-
vey on the screening and diagnosis of FASD in Australia.
The survey was distributed as an online password-
protected questionnaire using a secure web server. The
questionnaire was delivered to participants using HTML
forms which enabled participant responses to be saved
to and retrieved from a secure MySQL database. The
online questionnaire was pretested by 16 clinicians and
health researchers to ensure that the instrument was
clear and comprehensible, that the online format func-
tioned on a range of web browsers and operating sys-
tems, and that the questionnaire had face validity.
An email containing a personal username, password
and a link to the questionnaire website was sent to all
invited participants who were asked to complete the
questionnaire within 14 days. Email reminders were sent
approximately 7 days and 2 days prior to the response
deadline. The response deadline was subsequently
extended by 8 days to facilitate an improved response,
and one attempt to contact non-responders was made
by telephone for 43 non-responders for whom we had
telephone contact information.Analysis
Descriptive statistics were generated for each question
using PASW Statistics version 18.0.1 (SPSS Inc., 2009).
The chi-square test was used to assess associations
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used for 2 by 2 tables where any expected cell values
were less than 5. All analyses were evaluated with two-
tailed test statistics and effect sizes are described using
proportions, or risk ratios with 95% confidence intervals
(CI). The statistical analyses presented here are explora-
tory, and no adjustment has been made for multiple
comparisons.
Qualitative data were independently coded and ana-
lysed by two investigators using qualitative inductive
content analysis methods [22,23]. Data from each open
ended question were reviewed alongside the quantitative
data and coded inductively based on the underlying
meaning of the responses. Coding schemes used by both
analysts were documented and reviewed for consistency
to ensure the credibility and trustworthiness of the ana-
lysis process [22]. Approval for this study was granted by
The University of Western Australia Human Research
Ethics Committee and the Western Australian Aborigi-
nal Health Information and Ethics Committee.
Results
Of the 139 health professionals surveyed, 92 (66.2%)
responded to the questions on existing diagnostic guide-
lines (Table 1). Participants included 38 paediatricians
(41.3%), 23 non-paediatrician medical practitioners
(25.0%) and 31 other health professionals (33.7%), in-
cluding nurses, allied health professionals and clinical
researchers. Three quarters of participants were female,
and paediatricians were less likely to be female (50.0%)
than other participants (92.6%) (χ2 (1, N = 92) = 22.3, p
< 0.001). Participants were predominantly Australian
residents (91.3%), and five of the eight international par-
ticipants were residents of New Zealand. Over a quarter
of participants (26.7%) had completed specific training
in the diagnosis of FASD and 76.7% reported experience
in either the screening or diagnosis of FASD. Paediatri-
cians were more likely to have been involved in diagno-
sis (75.7%) than other participants (25.9%) (χ2 (1,
N = 90) = 22.3, p< 0.001).
Familiarity with existing diagnostic guidelines
Among the 92 participants, 38.0% were not familiar with
any diagnostic guideline, 21.7% were familiar with 1
guideline, 13.0% were familiar with 2 guidelines and
27.2% were familiar with 3 or more guidelines. Approxi-
mately half of participants were familiar with the UW
guidelines, and over a third of participants were familiar
with the Canadian guidelines (Table 2). Paediatricians
were more likely to be familiar with the CDC guidelines
than other health professionals (Table 2). Familiarity
with one or more guidelines was associated with occupa-
tional group, country of residence, experience in diagno-
sis, and completion of training in diagnosis (Table 3).Use of existing diagnostic guidelines
Among the 57 participants who were familiar with one
or more guidelines, 29.8% had not used any guideline,
40.4% had used one guideline, 19.3% had used two
guidelines and 10.5% had used three or more guidelines.
The UW and Canadian guidelines were the two most
frequently used guidelines, and over half of the partici-
pants who reported being familiar with these guidelines
also reported having used them (Table 2). These findings
indicated that as a proportion of all 92 participants,
43.5% reported use of any guideline, 27.2% reported use
of the UW guidelines, and 18.5% reported use of the
Canadian guidelines. Among participants who were fa-
miliar with the UW guidelines, paediatricians were 1.7
(95%CI 1.0-3.0) times more likely to have used the UW
guidelines (71.4%) than other health professionals
(41.7%, Table 2).
Participants who had experience in diagnosis were 1.8
(95%CI 1.1-2.8) times more likely to report using one or
more guidelines (84.8%) compared with those who did
not have experience in diagnosis (47.8%, Table 3). Ana-
lysis of the association between use of the UW and Can-
adian guidelines (the two most frequently used
guidelines) and country of residence, experience in diag-
nosis and completion of training found that inter-
national participants were 2.1 (95%CI 1.2-3.6) times
more likely to have reported using the Canadian guide-
lines (87.5%) than Australian participants (41.7%)
(p = 0.04, Fisher’s exact test). There was only weak evi-
dence of a similar trend for the UW guidelines, with
international participants 1.7 (95%CI 1.1-2.7) times more
likely to have reported using the UW guidelines (85.7%)
than Australian participants (50.0%); (p = 0.11, Fisher’s
exact test).
Participants who had experience in diagnosis were 2.9
(95%CI 1.2-7.0) times more likely to have used the UW
guidelines (72.4%) than participants who did not have
experience in diagnosis (25.0%) (χ2 (1, N= 45) = 9.7,
p = 0.002). Similarly, participants who had completed
training in diagnosis were 2.7 (95%CI 1.5-4.7) times
more likely to have used the UW guidelines (88.9%) than
participants who had not completed training in diagno-
sis (33.3%) (χ2 (1, N= 45) = 14.9, p< 0.001). There was
only weak evidence of a similar trend for the Canadian
guidelines, with participants who had experience in diag-
nosis 1.8 (95%CI 0.8-4.0) times more likely to have used
the Canadian guidelines (64.7%) than participants who
did not have experience in diagnosis (35.7%) (χ2 (1,
N = 31) = 2.62, p = 0.11). There was no evidence that par-
ticipants who had completed training in diagnosis were
more likely (risk ratio = 1.1, 95%CI 0.5-2.1) to have used
the Canadian guidelines (52.9%) than participants who
had not completed training in diagnosis (50.0%) (χ2 (1,
N = 31) = 0.03, p = 0.87). The power of these analyses is
Table 2 Comparison of familiarity with and use of existing diagnostic guidelines between paediatricians and other
occupations
Guideline Familiar with guideline Used guideline†
n (valid % of Occupation n) n (valid % of Familiar n)
All Paediatrician (n = 37)* Other (n = 54)* p{ All Paediatrician Other p{
IOM (n = 88) 27 (30.7) 12 (33.3) 15 (28.8) 0.65 8 (29.6) 3 (25.0) 5 (33.3) 0.70
UW (n= 89) 45 (50.6) 21 (58.3) 24 (45.3) 0.23 25 (55.6) 15 (71.4) 10 (41.7) 0.04
CDC (n = 90) 28 (31.1) 16 (43.2) 12 (22.6) 0.04 12 (42.9) 8 (50.0) 4 (33.3) 0.38
Canadian (n = 91) 32 (35.2) 15 (40.5) 17 (31.5) 0.38 17 (53.1) 8 (53.3) 9 (52.9) 0.98
Hoyme (n = 88) 12 (13.6) 6 (16.7) 6 (11.5) 0.54 6 (50.0) 2 (33.3) 4 (66.7) -
IOM-Institute of Medicine guidelines; UW-University of Washington 4-Digit Diagnostic Code; CDC-Centers for Disease Control and Prevention guidelines; Canadian-
Canadian guidelines; Hoyme-Hoyme et al. clarification of Institute of Medicine guidelines.
†Only participants who were familiar with a guideline were required to respond to this question.
{2-tailed p-value for chi-square (or Fisher’s exact) test comparing the proportion of paediatricians versus other occupations. Results not reported for all
comparisons due to small numbers.
*Denominators vary due to missing data, as summarised in column 1.
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reported having used the UW or Canadian diagnostic
guidelines.
Adoption of existing diagnostic guidelines
Approximately one third of participants who were famil-
iar with the UW guidelines recommended that they be
adopted in Australia, as did 30.8% of participants who
were familiar with the Canadian guidelines. In compari-
son, almost two thirds of participants who were familiar
with the Hoyme guideline, and just less than half of par-
ticipants who were familiar with the IOM guideline,
recommended that they not be adopted in Australia
(Table 4).
The perceived presence or absence of limitations for
the five guidelines is summarised in Table 4. The pro-
portion of participants who identified limitations for aTable 3 Individual characteristics and familiarity with and use
Characteristic Familiar with one or more guidelines
yes n (%) no n (%)
Occupation
paediatrician 30 (78.9) 8 (21.1)
other 27 (50.0) 27 (50.0)
Country of residence
Australia 49 (58.3) 35 (41.7)
other 8 (100) 0 (0.0)
Experience in diagnosis{
yes 33 (82.5) 7 (17.5)
no 23 (46.0) 27 (54.0)
Completed training{
yes 22 (91.7) 2 (8.3)
no 34 (51.5) 32 (48.5)
†Participants who were not familiar with a guideline were not required to respond
question or who indicated that the question was outside their area of expertise.
{Due to missing data, actual n is lower than reported in the column heading.specific guideline was highest for the Hoyme guideline.
Coding of the qualitative data identified seven categories
of perceived limitations that were either not specific to
any single guideline, or that were reported for two or
more guidelines. These included: i) that existing guide-
lines had not been demonstrated as relevant for the Aus-
tralian population, including the lack of Australian
normative data, particularly for the assessment of facial
characteristics among Indigenous Australians and those
from culturally diverse backgrounds; ii) the use of the
diagnostic terminology ‘alcohol-related’, which implies
that alcohol is ‘the causative factor’ for neurodevelop-
mental disorder; iii) limitations of methods used to
evaluate prenatal alcohol exposure: including that
under-diagnosis of neurodevelopmental disorders may
occur in cases of suspected but unconfirmed alcohol ex-
posure, or when exposure is unknown, such as in fosterof one or more existing diagnostic guidelines
(n = 92) Used one or more guidelines† (n = 57)
p yes n (%) no n (%) p
0.004 0.26
23 (76.7) 7 (23.3)
17 (63.0) 10 (37.0)
0.02 0.09
32 (65.3) 17 (34.7)
8 (100) 0 (0.0)
<0.001 0.003
28 (84.8) 5 (15.2)
11 (47.8) 12 (52.2)
<0.001 0.10
18 (81.8) 4 (18.2)
21 (61.8) 13 (38.2)
to these questions. Also excludes participants who did not respond to the
Table 4 Health professionals’ perceptions about the adoption of existing diagnostic guidelines
Guideline Recommend adoption† Identified limitations†
total n yes n (%) unsure n (%) no n (%) total n yes n (%) unsure n (%) no n (%)
IOM 25 1 (4.0) 13 (52.0) 11 (44.0) 21 7 (33.3) 11 (52.4) 3 (14.3)
UW 40 13 (32.5) 20 (50.0) 7 (17.5) 31 12 (38.7) 13 (41.9) 6 (19.4)
CDC 23 2 (8.7) 13 (56.5) 8 (34.8) 22 6 (27.3) 11 (50.0) 5 (22.7)
Canadian 26 8 (30.8) 14 (53.8) 4 (15.4) 22 8 (36.4) 9 (40.9) 5 (22.7)
Hoyme 11 1 (9.1) 3 (27.3) 7 (63.6) 9 7 (77.8) 1 (11.1) 1 (11.1)
IOM-Institute of Medicine guidelines; UW-University of Washington 4-Digit Diagnostic Code; CDC-Centers for Disease Control and Prevention guidelines; Canadian-
Canadian guidelines; Hoyme-Hoyme et al. clarification of Institute of Medicine guidelines.
†Participants who were not familiar with a guideline were not required to respond to these questions. Also excludes participants who did not respond to the
question or who indicated that the question was outside their area of expertise.
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confirmed alcohol exposure was considered ‘too gross a
measure’ of exposure; iv) the use of ‘less conservative
case definitions around central nervous system abnor-
mality, facial features and growth impairment’ which
lack specificity may lead to over-diagnosis, including use
of the 10th percentile criterion for palpebral fissure
length and the requirement for only 2 facial features for
a diagnosis of FAS; v) a ‘heavy emphasis on dysmorphol-
ogy assessment’ including the use of physical abnormal-
ities as the sole basis of the FAS diagnostic criteria, and
a perceived ‘over emphasis on occipital frontal circum-
ference’; and conversely, that the need for evidence of
significant central nervous system dysfunction and a ‘re-
liance on testing for the 9 central nervous system
domains’ might ‘prevent a diagnosis of FAS from being
rendered in children under the age of 8 years’ when
‘early accurate diagnosis is paramount to effective inter-
vention’; vi) the lack of use of an interdisciplinary ap-
proach to diagnosis, or alternatively, that an
interdisciplinary team for diagnosis is ‘not always avail-
able’; and vii) a general lack of evidence to support
guideline recommendations, including the perception
that the evidence for the amalgamation of the compo-
nents of other guidelines is unclear.
In addition, the following perceived limitations were
reported: that the IOM guidelines lack objectivity and
rigour, including use of a ‘gestalt approach’ to assess fa-
cial features which ‘is not sufficiently case-defined to
render accurate and consistent diagnoses under the um-
brella of FASD’; that the Hoyme guidelines are ‘the only
diagnostic system that maintains the classification of
alcohol-related birth defects’ which has been omitted
from other diagnostic guidelines; that the UW guidelines
are ‘too complex to be useable clinically outside of re-
search’, include ‘too many possible diagnoses’, that train-
ing was considered necessary to use these guidelines,
and that ‘the language should be modified for clinical
utility’; and that the CDC guideline ‘only provides diag-
nostic criteria for full FAS’.All participants were also asked why they did or did
not use any of the five diagnostic guidelines. Responses
from 47 participants (51.1%) indicated that diagnosis
was outside their area of expertise, that they only con-
tribute to diagnosis (i.e. conduct relevant assessments
that inform diagnosis, but do not make the final diagno-
sis), or that they only refer cases for diagnosis, and 13
participants (14.1%) did not respond to the question.
Among the remaining 32 participants, use of diagnostic
guidelines was based on: their familiarity with the guide-
line or completion of training based on a specific guide-
line (34.4%); relevance and ease of use in the clinical
context, including use across the lifespan or in settings
where alcohol exposure cannot be confirmed, and the
need to consider many different conditions and causes
(34.4%); the validated, objective and comprehensive na-
ture of the guideline (18.8%); the use of information or
tools from a number of guidelines to inform clinical
judgement as the guidelines are ‘not set in concrete’
(25.0%); and problems with the practical application of
guidelines in a clinical environment, including complex-
ity, time constraints, and disagreement with the content
of guidelines (21.9%).
Comments were received from 26 participants on the
adoption of existing FASD diagnostic guidelines in Aus-
tralia. They indicated: that a standard national approach,
based on the adoption and adaption of existing guide-
lines, and which is valid in the Australian context and
appropriate for use in rural and remote areas, is required
(26.9%); that providing education, training and support
for health professionals who are going to use the diag-
nostic tool is key (23.1%); that an inclusive, interdiscip-
linary and inter-agency model of service delivery is
required which engages parents and carers and ensures
access to diagnostic, intervention and support services
(23.1%); that Australian normative data are required,
particularly for facial norms among Indigenous Austra-
lians (19.2%); that an Australian guideline must be easy
to understand and practical to use (11.5%); that specific
guidelines should be adapted for use in Australia
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should be used to supplement clinical examination of fa-
cial dysmorphology (7.7%). One participant (3.8%) also
recommended the use of newer scientific methods in-
cluding functional neurological imaging techniques.Discussion
Participants were most familiar with, most frequently
used, and most frequently supported the adoption of the
UW and Canadian guidelines in Australia. However, no
single existing guideline received a high level of agree-
ment about its adoption for use in Australia, and partici-
pants were most likely to indicate that they were unsure
about whether existing guidelines should be adopted. Al-
though participants in our study were recruited based
on their expertise with or involvement in the screening
and diagnosis of FASD, only 43.5% of participants had
used diagnostic guidelines for FASD, and there was gen-
eral uncertainty about the suitability of existing guide-
lines for use in Australia. Our findings are consistent
with the limited knowledge about FAS among health
professionals [18], perceptions that it is more difficult to
diagnose FAS among Indigenous Australians [18,24], the
lack of national recommendations on diagnosis in Aus-
tralia, and the limited availability of information on the
comparative performance of existing diagnostic guide-
lines to inform clinical decision making.
When evaluating the suitability of existing diagnostic
guidelines for use in Australia, participants recognised a
need for guidelines that are evidence based, relevant to
the local clinical context, easy to use, and accompanied
by appropriate training and on-going support. Research
to address these needs and establish evidence to support
the national adoption of standard diagnostic methods is
required to improve the diagnostic capacity for FASD in
Australia. The importance of establishing an evidence
base for diagnostic and management practices is further
reinforced by research which indicates that FAS may not
be diagnosed if service providers do not believe that it
will make a difference to the individual [25].
The perceived limitations of existing diagnostic guide-
lines that were identified by participants in this study
correspond with limitations identified in the literature,
and many represent current challenges to the effective
diagnosis of individuals with FASD [1,11]. Although the
UW guidelines were recognised as having been devel-
oped based on empirical data, they were not always con-
sidered practical for the clinical setting. In contrast, the
Canadian guidelines, which integrate elements of the
UW and IOM approaches to diagnosis, and were devel-
oped based on published literature, expert opinion and
best practices [7], were not always considered evidence
based.As acknowledged in the Canadian guidelines, a lack of
evidence in key areas, including growth reference stan-
dards for all cultural groups, and of screening tools spe-
cific and sensitive to prenatal alcohol exposure, limits
the effectiveness of the current diagnostic process [7].
Canadian palpebral fissure length growth charts [26],
which have recently been found to be applicable to chil-
dren in the United States [27], are likely to be suitable
for use in Australia; however, their appropriateness
requires formal evaluation. Australian standards for In-
digenous Australians also need to be developed. The
lack of evidence can also be problematic where limita-
tions of current diagnostic methods, such as the absence
of identified biological markers of alcohol exposure dur-
ing pregnancy, preclude the diagnosis of neurodevelop-
mental disorders where there is no confirmed evidence
of prenatal alcohol exposure, despite information sug-
gesting that alcohol exposure is likely. Diagnostic meth-
ods for FASD will be facilitated by improvements in
medical technology and increased understanding of the
disorders [16].
The UW and Canadian guidelines are similar, with
both covering a spectrum of diagnostic outcomes, ex-
cluding the diagnostic category of alcohol-related birth
defects, and including almost identical diagnostic criteria
[16]. As highlighted by participants, these two guidelines
also have important differences, including the diagnostic
terminology used and the definition of central nervous
system abnormalities. The terminology used in the UW
guidelines was both perceived as being too complex, and
preferred for eliminating the implication that alcohol is
the primary causative factor for these disorders. The cri-
teria for central nervous system abnormality included in
the Canadian guidelines were also perceived as restrict-
ive due to their reliance on testing for central nervous
system dysfunction, which may not be possible in young
children and therefore may decrease the likelihood of
early diagnosis.
Perceptions of the strengths and limitations of diagnos-
tic guidelines may conflict, and are likely to reflect: i) vari-
ation in the nature of the guidelines examined, including
their evidence base and method of development; and ii)
variation in individual characteristics, beliefs, experience
and knowledge, including the context of experience, and
extent of familiarity with diagnostic guidelines for FASD.
In this study the perceived limitations of existing guide-
lines were evaluated in the context of their use in Austra-
lia, and our findings may not reflect their perceived
limitations in other contexts. The ability of participants to
make more general comparative evaluations among guide-
lines was also constrained by the small proportion of par-
ticipants who were familiar with more than one guideline.
As a result, perceived limitations reported for one guide-
line may also apply to other guidelines.
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perceptions of guidelines and the inability of many parti-
cipants to evaluate multiple guidelines, an understanding
of perceptions about existing guidelines enables consid-
eration of factors influencing the utility and adoption of
existing guidelines in Australia. Reported issues and
identified needs may be addressed through guideline de-
sign and implementation, training, research, and health
policy. Although the reported limitations provide valu-
able information, not all can be addressed in the short
term. Some perceptions highlight current challenges to
diagnosis irrespective of the guideline used, and
reinforce appreciation of the need for improved tech-
nologies for diagnosis. Other perceptions highlight pol-
icy issues relevant to FASD diagnosis in Australia that
need to be addressed. These include the lack of sufficient
resources to enable access to interdisciplinary diagnostic
assessment in Australia despite clear consensus in the
literature on the need for interdisciplinary team assess-
ment for FASD diagnosis [4-7], the need for a standard
national approach to diagnosis, and the lack of evidence
base to support accurate and appropriate diagnosis, sur-
veillance and management in the Australian context.
The validity of our findings is supported by the evi-
dence of association found between individual character-
istics and familiarity with and use of existing diagnostic
guidelines. Health professionals who had not completed
specific training in diagnosis had poorer knowledge of
diagnostic guidelines for FASD. This finding is consist-
ent with previous work indicating that many paediatri-
cians identified their need for educational materials on
diagnosis [24]. Participants who reported experience in
diagnosis and completion of specific training in FASD
diagnosis were also more likely to report having used the
UW guidelines, consistent with both the prominent use
of the UW guidelines internationally [12] and the acces-
sibility of comprehensive online training in the UW
diagnostic methods [28], which we found to be a factor
influencing the use of a specific guideline. These findings
also highlight areas where policy and education could
strengthen diagnostic capacity for FASD.
This survey was conducted within a larger study of
health professionals’ perceptions of FASD diagnosis in
Australia, and the length of the questionnaire may have
discouraged participation among some individuals. We
purposively sampled participants to identify health
professionals who had expertise in or experience with
the screening or diagnosis of FASD and could provide
information relevant to the adoption of national
diagnostic guidelines. As such, our findings are not
generalisable to all health professionals in Australia. A
small sample of international participants with recog-
nised expertise in FASD was also recruited, and the dif-
ferences demonstrated in responses between Australianand international participants reflect both the nature of
the sampling process and the lack of progress on the im-
plementation of standard diagnostic guidelines for FASD
in Australia.
Despite the targeted recruitment of health profes-
sionals in this study, our findings were limited by the
small number of participants who had used existing
diagnostic guidelines and could evaluate their suitability
in the Australian context. Participant perceptions of the
limitations of existing systems may also vary based on a
range of factors, including the clinical context in which
the guidelines are used. Nevertheless, the participating
health professionals indicated support for a national
guideline, provided valuable information about the suit-
ability of existing guidelines for the Australian context,
and identified factors which may influence adoption and
help ensure the appropriateness of national recommen-
dations for diagnosis. This survey was conducted to
enable evidence from a national consultation and con-
sensus development process with health professionals to
be considered in the design of an Australian diagnostic
instrument for FASD. The national approach to develop-
ment will utilise findings from this survey, findings from
the broader consultation process, and evidence from the
published literature.
Conclusions
Our findings demonstrate a lack of certainty among
health professionals about the most appropriate guide-
line for use in Australia, and some support for the adop-
tion of the UW or Canadian guidelines. Nevertheless,
health professionals endorsed the need for national diag-
nostic guidelines for FASD, and the need for their evalu-
ation in the Australian context to ensure that the
guidelines are feasible, nationally applicable, valid, and
acceptable to both health professionals and consumers.
Health professionals support a nationally coordinated
approach to the diagnosis of FASD. This should incorp-
orate standard diagnostic criteria, include an interdiscip-
linary and interagency model of service delivery, and
address health professionals’ concerns about existing
diagnostic criteria. Training and support for service pro-
viders in the use of the diagnostic guidelines would be
necessary to increase diagnostic capacity in Australia.
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